AI can help to design drug candidates, but as Ruxanda Teslo argues on Asimov Press, it’s not going to lead to therapeutic abundance anytime soon. That’s because clinical trials, which represent the biggest drug development cost, are unlikely to become much shorter or cheaper because of AI. I am continuing to be confident in my prediction that AI will not lead to a massive increase (more than 2-fold) in FDA approvals in the next ten years.
Thanks to Marginal Revolution for the pointer to Teslo’s post.
Nehaveigur 